Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
In the U.S. today, frontline cancer treatments are being rationed. ERs are short on sedatives. Amoxicillin—one of the most prescribed antibiotics in the country—has been in critical shortage. These are not temporary disruptions. They reflect a structural breakdown caused by the erosion of America’s pharmaceutical manufacturing base and a decades-long surge in generic drug imports.
U.S. based generic drug makers need government support to expand – and maybe even to survive – the onslaught of imports nearly every member of the House Energy and Commerce Committee Subcommittee on Health said in a hearing on Wednesday.
The American pharmaceutical supply chain has become dangerously dependent on imports and foreign-controlled supply chains. Over the past 20 years, the country has experienced a skyrocketing rate on pharmaceutical imports and increasing foreign reliance.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
President Trump’s Executive Order is a bold, necessary move to rebuild America’s pharmaceutical industry and protect our citizens.
President Trump’s action to close the de minimis loophole for China is a monumental victory for American workers, manufacturers, and national security.
The IPO, widely seen as the first major test of President Trump’s America First Investment Policy (AFIP), directly undermines the President’s February directive to block U.S. investment in companies linked to the Chinese military, human rights abuses, and authoritarian surveillance state.
